CUV Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$21,975.00
Insider Selling (Last 12 Months): A$1,342,566.95

Clinuvel Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Clinuvel Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Clinuvel Pharmaceuticals Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for CUV up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Clinuvel Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/4/2022Jeffrey RosenfeldInsiderBuy300A$19.44A$5,832.00
6/16/2022Brenda ShanahanInsiderSell15,000A$14.04A$210,540.00
5/10/2022Philippe WolgenInsiderBuy1,000A$16.14A$16,143.00
3/22/2022Philippe WolgenInsiderSell55,606A$20.36A$1,132,026.95
1/14/2022Brenda ShanahanInsiderExpiry25,000A$25.13A$628,250.00
6/24/2021Brenda ShanahanInsiderSell25,000A$27.67A$691,775.00
5/31/2021Philippe WolgenInsiderSell102,700A$30.45A$3,127,317.70
3/2/2021Jeffrey RosenfeldInsiderBuy670A$22.24A$14,898.12
See Full Table

SEC Filings (Institutional Ownership Changes) for Clinuvel Pharmaceuticals (ASX:CUV)

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Read More on Clinuvel Pharmaceuticals

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

124,193 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

0.18%

Beta

N/A

Who are the company insiders with the largest holdings of Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals' top insider shareholders include:
  1. Brenda Shanahan (Insider)
  2. Jeffrey Rosenfeld (Insider)
  3. Philippe Wolgen (Insider)
Learn More about top insider investors at Clinuvel Pharmaceuticals.